Drugs / 9-valent HPV Recombinant Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03676101 | Oct 2018 → Aug 2019 | adenocarcinoma in situ, anogenital human papillomavirus infection, cervical cancer, cervical intraepithelial neoplasia grade 2/3 +4 | Shanghai Bovax Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9-valent HPV Recombinant Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03676101 ↗ |
| Modality | Vaccine | “9-valent HPV Recombinant Vaccine” NCT03676101 ↗ |